The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer

Abstract

We first described the role of local radiation therapy (LT) for oligoprogressive disease (OPD) on targeted therapy in 2012. Here, we present an updated and larger dataset and extend the analysis beyond EGFR and ALK. MethodsA retrospective review of patients with metastatic NSCLC harboring EGFR/BRAF V600E mutations, or ALK/ROS1/RET rearrangements, who had OPD on respective tyrosine-kinase inhibitor (TKI) and treated with LT was performed. OPD was defined as disease progression on therapy in ≤5 sites. PFS1 (Progression-free survival 1) was defined as time from initiation of TKI-containing regimen to the first course of LT for OPD. Subsequent PFS times (i.e. PFS2, PFS3, etc.) were defined as time from prior LT to subsequent LT, switch of systemic therapy, death or loss to follow up, whichever occurred first. Extended-PFS was defined as time from the first day of the first LT course to the day of change in systemic therapy, death or loss to follow up, whichever came first. ResultsEighty-nine patients were identified. In 75.4% of the LT courses, a single lesion was treated. Median PFS1 was 10.2 months (95% CI 8.7-13.1) and median Extended-PFS was 6.7 months (95% CI: 4.9-8.3). Extended-PFS was similar across different oncogenic drivers. 51.4% of patients who underwent LT to a single site had only 1 site on next disease progression. ConclusionsLT is effective in prolonging treatment duration on TKI in oncogene-addicted NSCLC across multiple oncogenes.